Effect of IFN-γ treatment andin vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killef (LAK) cell lysisin vitro; association with H-2 expression on the target cells
- 15 October 1989
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 44 (4) , 669-674
- https://doi.org/10.1002/ijc.2910440419
Abstract
Interferon-gamma (IFN-γ) treatment or in vivo passage of the murine YAC-I lymphoma resulted in reduced sensitivity to in vitro lysis by syngeneic murine spleen cells cultured in rlL-2 (LAK-cells). IFN-γ treatment also rendered the murine BI6 melanoma less sensitive to lysis by syngeneic LAK cells, whereas in vivo passage did not alter LAK sensitivity. The reduction in sensitivity to lysis correlated with enhanced expression of cell surface H-2 on the target cells. The possible role of H-2 was studied with a β2-microglobulin-deficient, and thus H-2-deficient, variant of the YAC-I lymphoma. This variant line remained H-2 negative even after IFN-γ treatment or in vivo passage, and was highly sensitive to LAK-cell-mediated lysis, even after IFN-γ treatment or in vivo passage. The present results are discussed in relation to IFN-γ and in vivo induced modulation of MHC class-l molecules on target cells and the possible consequences for interaction with activated as well as “natural” effector cells.This publication has 28 references indexed in Scilit:
- Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cellsCellular Immunology, 1989
- The protective effect of interferon against natural killing activity is not mediated via the expression of class I MHC antigensImmunology Letters, 1988
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gammaInternational Journal of Cancer, 1987
- In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cellsInternational Journal of Cancer, 1987
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Major histocompatibility antigens: The human (HLA-A,-B,-C) and murine (H-2K, H-2D) class I moleculesCell, 1981
- The isolation and characterization of the high-molecular-weight glycoprotein from pig colonic mucusBiochemical Journal, 1978